LIVINGSTON, NJ–(Marketwired – November 19, 2015) – Milestone Scientific’s (NYSE MKT: MLSS) Epidural & Intra-Articular Subsidiary today announced that it has submitted initial results of the Company’s prospective, open labeled, clinical trial assessing the CompuFlo® technology in correctly identifying the epidural space during an epidural procedure to a prestigious European pain management society in advance of this organization’s annual meeting in 2016.
Milestone Scientific’s Epidural & Intra-Articular Subsidiary designed the study, in conjunction with its Scientific Advisory Board, and in agreement with the U.S. Food and Drug Administration (FDA), to assess the safety and effectiveness of the pressure sensing technology in identification of the epidural space as part of acute and chronic pain management.
Successful and safe performance of epidural anesthesia or epidural injections relies on correct identification of the epidural space. 
Leonard Osser, Chief Executive Officer of Milestone Scientific added, “We are pleased to have submitted initial results of this prospective, open labeled, clinical trial to one of the most prestigious European pain management societies. Compuflo® technology was designed to confirm the epidural space in real time as opposed to the current 2 step approach, which may provide significant advantages for anesthesiologists and patients. The current process requires advancing an epidural needle via loss of resistance technique and then confirming the space by injecting contrast and visualizing it under X-ray fluoroscopy. Along with other benefits, our process has the potential to significantly reduce cost and avoid radiation exposure for the patients and medical practitioners.”
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) is a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies. Milestone’s computer-controlled systems make injections precise, efficient, and virtually painless. For more information please visit our website: www.milestonescientific.com.